RT Journal Article
SR Electronic
T1 Cancer inpatient with COVID-19: a report from the Brazilian National Cancer Institute
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.27.20141499
DO 10.1101/2020.06.27.20141499
A1 Andreia C. de Melo
A1 Luiz C.S. Thuler
A1 Jesse L. da Silva
A1 Lucas Z. de Albuquerque
A1 Ana C. Pecego
A1 Luciana de O.R. Rodrigues
A1 Magda S. da Conceição
A1 Marianne M. Garrido
A1 Gelcio L. Quintella Mendes
A1 Ana Cristina P. Mendes Pereira
A1 Marcelo A. Soares
A1 João P.B. Viola
A1 on behalf of the INCA COVID-19 Task Force
YR 2020
UL http://medrxiv.org/content/early/2020/07/07/2020.06.27.20141499.abstract
AB Brazil has been recording a frightening exponential curve of confirmed cases of SARS-CoV-2 infection. Cancer patients with COVID-19 are likely to have a greater risk of complications and death. A retrospective search in the electronic medical records of cancer inpatients admitted to the Brazilian National Cancer Institute from April 30, 2020 to May 26, 2020 granted identification of 181 patients with COVID-19 confirmed by RT-PCR method. The mean age was 55.3 years (SD ±21.1). The most prevalent solid tumors were breast (40 [22.1%]), gastrointestinal (24 [13.3%]), and gynecological (22 [12.2%]). Among hematological malignancies, lymphoma (20 [11%]) and leukemia (10 [5.5%]) predominated. The most common complications were respiratory failure (70 [38.7%]), septic shock (40 [22.1%]) and acute kidney injury (33 [18.2%]). A total of 60 (33.1%) patients died due to COVID-19 complications. By multivariate analysis, cases with admission due to symptoms of COVID-19 (p = 0.027) and with two or more metastatic sites (p <0.001) showed a higher risk of COVID-19-specific death. This is the first study in a cohort of Brazilian cancer patients with COVID-19. The rates of complications and COVID-19-specific death were significantly high. Our data prompts urgent and effective public policies for this group of especially vulnerable patients.Statement of Significance COVID-19-specific mortality in cancer inpatients is markedly higher than in the general population and the cases with advanced cancer are particularly in a more vulnerable group. Adaptations of cancer management guidelines and more intensive preventive measures should be a priority for this group of patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants to LCST from CNPq (306798/2019-0), to MAS from CNPq (305765/2015-9) and FAPERJ (E-26/202.894/2017) and to JPBV from CNPq (307042/2017-0) and FAPERJ (202.640/2019, 211.562/2019 and 010.000162/2020). LZA was supported by a PIBIC/CNPq fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the National Commission of Ethics in Research (CONEP) and conducted in accordance with the Good Clinical Practice guidelines.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made available upon written request to the Corresponding author by e-mail.